一线化疗后无基线疾病证据的患者接受尼拉帕利维持单药治疗时卵巢癌首次复发模式:PRIMA/ENGOT-OV26/GOG-3012 的事后亚组分析
该事后亚组分析基于 3 期 PRIMA/ENGOT-OV26/GOG-3012 研究,评估一线化疗后无疾病证据、随机接受尼拉帕利维持治疗的晚期卵巢癌患者首次复发模式;314 例中 190 例出现新病灶,93.2% 为 1-3 个病灶,常见部位为腹膜、淋巴结和肝脏;作者认为需前瞻性评估局部治疗联合持续全身靶向维持治疗能否改善结局。
要点
- 314 例尼拉帕利治疗患者中 190 例出现至少 1 个新病灶,新病灶数中位为 1.0 个(四分位距 1-2)。
- 190 例中 93.2%(177/190)首次进展时为 1-3 个病灶,常见部位为腹膜 30.0%(57/190)、淋巴结 26.3%(50/190)、肝脏 20.5%(39/190)。
- 同源重组修复缺陷、IV 期或间歇性减瘤史者新病灶数中位为 1.0 个,同源重组修复正常、III 期或初次减瘤史者为 2.0 个。
核心结论
- 许多一线维持治疗开始时无病灶的晚期卵巢癌患者首次复发时表现为寡转移性疾病;需前瞻性评估局部治疗联合持续全身靶向维持治疗能否改善这些患者的结局。
研究设计与样本
- PRIMA/ENGOT-OV26/GOG-3012 研究的事后亚组分析,仅纳入随机接受尼拉帕利维持治疗且基线无疾病证据的高疾病进展风险晚期卵巢癌患者,评估研究者判定的疾病进展时首次复发病灶数量和部位。
主要发现
- 314 例尼拉帕利治疗患者中 190 例出现至少 1 个新病灶,新病灶数中位为 1.0 个(四分位距 1-2)。
- 190 例中 93.2%(177/190)首次疾病进展时出现 1-3 个病灶。
- 最常见复发部位为腹膜 30.0%(57/190)、淋巴结 26.3%(50/190)、肝脏 20.5%(39/190)。
- 按生物标志物状态、诊断时疾病分期和减瘤手术类型分层,结果相似。
- 同源重组修复正常、III 期疾病或初次减瘤手术史患者首次进展时新病灶数中位为 2.0 个;同源重组修复缺陷、IV 期疾病或间歇性减瘤手术史患者为 1.0 个。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patterns of disease recurrence on poly(ADP-ribose) polymerase inhibitor maintenance therapy are unclear and may affect subsequent treatment. This ad hoc subgroup analysis of the phase 3 PRIMA/ENGOT-OV26/GOG-3012 study evaluated patterns of initial recurrence in patients with advanced ovarian cancer (AOC). METHODS: PRIMA included participants at high risk for disease progression. This ad hoc analysis only evaluated participants randomized to niraparib maintenance without evidence of disease at baseline. The number and site(s) of initial recurrent lesions at investigator-assessed progressive disease (PD) were evaluated. RESULTS: Of the 314 niraparib-treated patients analyzed, 190 developed ≥1 new lesion (median number of new lesions, 1.0; interquartile range, 1-2). In total, 93.2% (177/190) of patients developed 1-3 lesions at first disease progression. The most common sites of recurrence were the peritoneum (30.0% [57/190]), lymph nodes (26.3% [50/190]), and liver (20.5% [39/190]). Similar results were observed when patients with PD were stratified by biomarker status, disease stage at diagnosis, and type of debulking surgery. Patients with homologous recombination-proficient tumors, stage III disease, or a history of primary debulking developed a median of 2.0 new lesions at first progression; patients with homologous recombination-deficient tumors, stage IV disease, or a history of interval debulking developed a median of 1.0 new lesion. CONCLUSIONS: Many patients with AOC without lesions at first-line maintenance treatment initiation develop oligometastatic disease at first recurrence. Prospective evaluation is required to determine whether these patients have improved outcomes when local therapies are combined with continuous, systemic, targeted maintenance therapy.
引用
- Kamrava MR, Gonzalez-Martin A, Pothuri B, et al. Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012. Gynecol Oncol. 2024. PMID: 39032397. doi:10.1016/j.ygyno.2024.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。